Experimental Weight-Loss Drug Gains Attention Amid Trump Usage Rumors
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
First reported by Walla · Jun 28, 2026
What happened
Reports that a 79-year-old received early access to the experimental weight-loss drug retatrutide sparked rumors about President Trump, which the White House denied. The case revealed the FDA's rare compassionate use pathway allowing access to unapproved drugs. Retatrutide shows promise in obesity treatment and metabolic health, with ongoing trials and potential for accelerated FDA review.
- 01A 79-year-old received special access to Eli Lilly's experimental drug retatrutide before FDA approval.
- 02Social media speculated the patient was President Trump; the White House denied this.
- 03The FDA's compassionate use pathway allows limited early access to unapproved drugs.
- 04Retatrutide acts on three hormonal pathways, showing weight loss comparable to bariatric surgery.
- 05Thousands receive retatrutide in global clinical trials, with some continuing post-trial.
- 06An unregulated gray market sells unverified versions of retatrutide online, posing risks.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
